← Back to Clinical Trials
Recruiting NCT06458569

NK-ORB Expression of Mu Receptor on Lymphocytes in Rehabilitation

Trial Parameters

Condition Fibromyalgia
Sponsor IRCCS San Raffaele Roma
Study Type OBSERVATIONAL
Phase N/A
Enrollment 50
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-10-03
Completion 2025-07-31
Interventions
Rehabilitation

Brief Summary

Chronic pain is a serious disorder that causes physical suffering and emotional distress. NK cells are cytotoxic granular cells playing a crucial role in innate immunity. Recent studies described modulation of the percentage of B lymphocytes and NK cells expressing the μ opioid receptor as a potential marker for measuring pain. Neuropathic pain sufferers have decreased NK cell function, highlighting the need of further investigating the effect of opioid receptor expression on lympoid cells defining their potential relevance as a pain monitor marker. Opioid receptors expressed on NK, B and T cells are a possible candidate for objective monitoring of pain in patients.

Eligibility Criteria

Inclusion Criteria: IRCCS San Raffaele Roma patients who entered the neuro-rehabilitation program, aged 18 years older, able to sign a written informed consent. Exclusion Criteria: * Patients with oncological or psychiatric diseases. * Pregnant patients * Patients with a severe psychiatric disorder (excluding mild depression) or mental/cognitive impairment

Related Trials